Protagonist Therapeutics, Inc (PTGX): Total Liabilities
$53.48M
As of 2025-12-31
$44.00M
As of 2026-06-30
+18.3%
3-year compound annual growth
+3.6%
5-year compound annual growth
+26.1%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $53.48M | -23.0% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $69.43M | +226.4% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $21.27M | -34.2% | 2025-02-21, Balance as of period end |
| 2022-12-31 | $32.32M | -32.2% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $47.67M | +6.3% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $44.86M | -40.1% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $74.95M | +178.0% | 2021-03-10, Balance as of period end |
| 2018-12-31 | $26.96M | -37.5% | 2020-03-10, Balance as of period end |
| 2017-12-31 | $43.10M | +569.8% | 2019-03-12, Balance as of period end |
| 2016-12-31 | $6.43M | +22.6% | 2018-03-07, Balance as of period end |
| 2015-12-31 | $5.25M | n/a | 2017-03-07, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $53.48M | -23.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $214.26M | +486.9% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $7.67M | +67.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $112.27M | -16.7% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $77.45M | -49.2% |
Compare PTGX, SEPN, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗